Dublin, May 15, 2018 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering.
The HNC Asia-Pacific market will be valued at $424.5m in 2023, growing from $265.9m in 2016 at a CAGR of 6.9%.
The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor). Historically, cytotoxic chemotherapies have made up the bulk of the HNC market.
Little competition currently exists in the HNC market, leaving an area of considerable opportunity for interested newcomers. Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.
With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea and Japan, there has been an increase in targeted therapy options. Additionally avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of the forecast period, as it is currently undergoing Phase III trials in Japan, Australia and South Korea. A number of mAbs are in development in HNC for the inhibition of various different pathways and signaling systems. Many companies are following a strategy of developing products with similar mechanisms of action to those of existing products already approved in either HNC or other oncology indications. EGFR and PD-1/PD-L1 are the most commonly addressed targets in the current pipeline.
However, there are also many innovative products in the HNC pipeline, which reflects a deepening scientific understanding of the underlying pathophysiology of HNC and the growing list of molecules that have been implicated in the initiation and progression of the disease.
The report "Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market" helps you to:
Scope
Key Topics Covered:
1 Table of Contents
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Etiology
2.4.2 Pathophysiology
2.4.3 Biomarkers/Targets of Interest
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Guidelines and Options
2.8.1 Surgery and Radiation Therapy
2.8.2 Chemotherapy
2.8.3 Targeted Therapies
3 Marketed Products
3.1 Overview
3.2 Chemotherapies
3.2.1 TS-1 (tegafur plus gimeracil plus oteracil) - Taiho Pharma
3.2.2 Cisplatin
3.2.3 Docetaxel
3.2.4 Fluorouracil (5-FU)
3.2.5 Methotrexate
3.3 Epidermal Growth Factor Receptor Targeted Therapies
3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA
3.3.2 BIOMAb EGFR (nimotuzumab) - Biocon/Biotech Pharmaceutical Co.
3.4 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
3.4.1 Opdivo (nivolumab) - Bristol-Myers Squibb
3.4.2 Keytruda (pembrolizumab) - Merck & Co.
3.5 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Imfinzi (durvalumab) - MedImmune
4.4.2 Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
4.4.3 Bavencio (avelumab) - Merck KgaA/Pfizer
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Molecule Type and Stage of Development
5.3.2 Trial Duration by Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics
6 Multi-scenario Forecast
6.1 Overview
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Incidence of HNC
7.1.2 Adoption of Immuno-oncology Therapies in the HNC Treatment Algorithm
7.1.3 Launch of Premium Priced Pipeline Products
7.1.4 Increasing Usage of High Premium Priced Combination Therapies
7.1.5 Diversified Healthcare Reform and Insurance System to Boost Market Growth
7.2 Barriers
7.2.1 Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate
7.2.2 Patent Expiration of Branded Therapies to Affect HNC Market Growth
7.2.3 Lack of Development of Pipeline Products for Locally Advanced HNC
7.2.4 High Prices of Therapeutics, Lack of Reimbursement and Penetration of Generics to Slow Down Market Growth in China and India
7.2.5 Drug Pricing Reforms
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.2 Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/lp26wz/head_and_neck?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs